Definitive evidence for Club cells as progenitors for mutant Kras/Trp53‐deficient lung cancer

Accumulating evidence suggests that both the nature of oncogenic lesions and the cell‐of‐origin can strongly influence cancer histopathology, tumor aggressiveness and response to therapy. Although oncogenic Kras expression and loss of Trp53 tumor suppressor gene function have been demonstrated to initiate murine lung adenocarcinomas (LUADs) in alveolar type II (AT2) cells, clear evidence that Club cells, representing the second major subset of lung epithelial cells, can also act as cells‐of‐origin for LUAD is lacking. Equally, the exact anatomic location of Club cells that are susceptible to Kras transformation and the resulting tumor histotype remains to be established. Here, we provide definitive evidence for Club cells as progenitors for LUAD. Using in vivo lineage tracing, we find that a subset of Kras12V‐expressing and Trp53‐deficient Club cells act as precursors for LUAD and we define the stepwise trajectory of Club cell‐initiated tumors leading to lineage marker conversion and aggressive LUAD. Our results establish Club cells as cells‐of‐origin for LUAD and demonstrate that Club cell‐initiated tumors have the potential to develop aggressive LUAD.

[1]  F. Shah,et al.  Putative stemness markers octamer-binding transcription factor 4, sex-determining region Y-box 2, and NANOG in non-small cell lung carcinoma: A clinicopathological association , 2020, Journal of Cancer Research and Therapeutics.

[2]  A. Berns,et al.  Cells of origin of lung cancers: lessons from mouse studies , 2020, Genes & development.

[3]  A. Regev,et al.  Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. , 2020, Cancer cell.

[4]  Jason D. Buenrostro,et al.  Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. , 2020, Cancer cell.

[5]  Josiah J. An,et al.  Transformational Changes Between Non-Small Cell and Small Cell Lung Cancer-Biological and Clinical Relevance-A Review. , 2020, American journal of clinical oncology.

[6]  K. Polyak,et al.  Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. , 2020, Cancer cell.

[7]  D. Pe’er,et al.  Lineage plasticity in cancer: a shared pathway of therapeutic resistance , 2020, Nature Reviews Clinical Oncology.

[8]  R. Liu,et al.  Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients , 2020, Scientific Reports.

[9]  S. Herold,et al.  Bronchioalveolar stem cells are a main source for regeneration of distal lung epithelia in vivo , 2019, The EMBO journal.

[10]  V. Aidinis,et al.  Club cells form lung adenocarcinomas and maintain the alveoli of adult mice , 2019, eLife.

[11]  Summer S. Han,et al.  Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. , 2019, Lung cancer.

[12]  M. Hellmich,et al.  K‐ras Mutation Subtypes in NSCLC and Associated Co‐occuring Mutations in Other Oncogenic Pathways , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  L. Moens,et al.  Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. , 2019, Lung cancer.

[14]  Akihiko Yoshida,et al.  Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Shengshou Hu,et al.  Lung regeneration by multipotent stem cells residing at the bronchioalveolar-duct junction , 2019, Nature Genetics.

[16]  M. Guo,et al.  Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations , 2019, BMC Cancer.

[17]  D. Schuppan,et al.  Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice. , 2018, Molecular pharmaceutics.

[18]  E. Migliore,et al.  Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. , 2018, Human pathology.

[19]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[20]  M. Ladanyi,et al.  Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[21]  P. Jänne,et al.  Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[23]  O. Kallioniemi,et al.  Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. , 2017, Cell reports.

[24]  Adam P. Rosebrock,et al.  Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma , 2016, Proceedings of the National Academy of Sciences.

[25]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[27]  S. Ikeda,et al.  Immunostaining for thyroid transcription factor 1, Napsin A, p40, and cytokeratin 5 aids in differential diagnosis of non-small cell lung carcinoma. , 2015, Oncology letters.

[28]  L. Sequist,et al.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. , 2015, The Lancet. Oncology.

[29]  Ya‐Wen Cheng,et al.  NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation , 2015, Oncotarget.

[30]  Thomas M. Keane,et al.  The mutational landscapes of genetic and chemical models of Kras-driven lung cancer , 2014, Nature.

[31]  Yun Lu,et al.  The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2 , 2014, Genes & development.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[33]  A. Berns,et al.  Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma , 2014, Proceedings of the National Academy of Sciences.

[34]  Zhaoyuan Fang,et al.  Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma , 2014, Nature Communications.

[35]  M. Krasnow,et al.  Alveolar progenitor and stem cells in lung development, renewal and cancer , 2014, Nature.

[36]  M. Barbacid,et al.  Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[37]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[38]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[39]  Yi-long Wu,et al.  Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Shan-Mei Xu,et al.  Alveolar Type II Cells Possess the Capability of Initiating Lung Tumor Development , 2012, PloS one.

[41]  Aftab Ahmad,et al.  Expression of Sox2 and Oct4 and Their Clinical Significance in Human Non-Small-Cell Lung Cancer , 2012, International journal of molecular sciences.

[42]  Yun Lu,et al.  Evidence for type II cells as cells of origin of K-Ras–induced distal lung adenocarcinoma , 2012, Proceedings of the National Academy of Sciences.

[43]  John Yu,et al.  Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma. , 2011, Cancer research.

[44]  A. Berns,et al.  Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. , 2011, Cancer cell.

[45]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  Jane E. Visvader,et al.  Cells of origin in cancer , 2011, Nature.

[47]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[48]  Fan Wang,et al.  The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. , 2009, Cell stem cell.

[49]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[50]  Y. Yatabe,et al.  Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. , 2007, Cancer research.

[51]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[52]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[53]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[54]  Y. Yatabe,et al.  TTF-1 Expression in Pulmonary Adenocarcinomas , 2002, The American journal of surgical pathology.

[55]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[56]  S. Linn,et al.  Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene , 2001, Oncogene.

[57]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[58]  A. Berns,et al.  Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.

[59]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[60]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[61]  S. Robinson,et al.  Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[62]  N. Dubrawsky.  Cancer statistics , 2022 .